Which GLP-1 Should I Start With? A 2026 Starter Guide

That probably sounds like a dodge. It isn't. The “best on paper” drug isn't always the one you should start with — and the thing that changes the answer is usually boring stuff like what your plan covers and whether you'll actually stick with a weekly shot. Below, we'll show you the few things that decide it, what each path costs right now, and how to start the smart way.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Quick answer: find your row, find your starting lane

Find the line that sounds most like you. The full reasoning — and the sources — is in the sections below.

The honest truth: no website can pick your exact GLP-1 — and that's the point

No website (and no AI) can safely choose a prescription drug for you without knowing your health history. That's not a weakness of this guide — it's the reason we built it. Our job is to help you walk into a prescriber visit already knowing your likely lane, the right questions to ask, and where to actually start.

Anyone who tells you “Drug X is the one, just buy it” is selling you something. We'd rather lose the sale and keep your trust. So here's our deal: we'll hand you the real decision framework, the current prices, and the honest tradeoffs — for free. You decide. A licensed clinician confirms it. That's how this should work.

The 5 questions that decide which GLP-1 you start with

Your starting medication is set by five things, in this order: your goal, your coverage, your format preference, your ongoing budget, and your medical history. Answer these five and the giant menu of “everything” shrinks to one or two real options. A prescriber then confirms it's safe for you.

1. 1What are you treating? Plain weight loss? Type 2 diabetes? Heart risk? Sleep apnea? PCOS or insulin resistance? The answer changes the label match and what insurance will pay for.
2. 2Will insurance cover any FDA-approved option? If yes, that often decides it — because the best starter is one you can afford to stay on.
3. 3Pill or shot? Be real with yourself. A pill you'll take beats a stronger shot you'll skip.
4. 4Can you afford month two — and month six? The $149 “first month” hook is not the real number. Maintenance pricing matters more.
5. 5Anything in your medical history that changes the rules? Pregnancy, pancreatitis, thyroid cancer history, severe stomach problems, certain meds. (Full red-flag list is below.)

Which GLP-1 should I start with for the most weight loss?

If maximum average weight loss is your top goal and you're okay with a weekly injection, Zepbound (tirzepatide) is the strongest first conversation to have with a clinician. In the first head-to-head trial — SURMOUNT-5, published in the New England Journal of Medicine in 2025 — tirzepatide produced greater average weight loss than semaglutide at 72 weeks: about 20.2% vs 13.7% of body weight.

So why isn't this an automatic “start with Zepbound”? Three reasons:

• Averages aren't promises. Some people lose more on semaglutide than the average person on tirzepatide. Your body isn't a clinical trial.
• Coverage may decide for you. If your plan covers Wegovy but not Zepbound (or the other way around), the covered one is usually the smarter start.
• The strongest drug you can't stay on helps no one. Cost, side effects, and supply all matter for the long haul.

Should I start with semaglutide or tirzepatide?

Tirzepatide usually wins on weight-loss magnitude; semaglutide may win on access, the heart-disease indication, insurance coverage, or pill availability. The right first choice is the one your clinician thinks you can safely afford and keep taking.

Should I start with a pill or a shot?

If needles are the thing stopping you, start with an FDA-approved pill — the Wegovy pill or Foundayo. Injections have the strongest and longest-studied weight-loss data, but a pill can be the better real-world start if it's the only format you'll keep taking.

Bottom line: don't pick the format that looks best on a chart. Pick the one you'll still be doing in six months.

Which GLP-1 should I start with if I have type 2 diabetes?

If you have type 2 diabetes, the starting question changes from “which weight-loss drug?” to “which diabetes-labeled medicine fits my blood sugar, heart and kidney risk, insurance, and weight goals?” Ozempic, Mounjaro, and Rybelsus are labeled for type 2 diabetes; Wegovy, Zepbound, and Foundayo are labeled for weight management. Your diagnosis can change both coverage and the cleaner label match.

For a deeper breakdown, see our guide to the best GLP-1 for diabetes.

Which GLP-1 should I start with if I have heart disease?

If you have established cardiovascular disease plus obesity or overweight, Wegovy deserves the first conversation — the FDA approved it to lower the risk of serious heart events (like heart attack and stroke) in that exact group.

• This indication is for people with known, established heart disease — not general “I'd like to protect my heart someday” risk.
• Your insurer may require documentation of your heart history to approve it.
• A clinician should still review your full picture — your medications, your cardiac history, and any reasons to avoid a GLP-1.
• On Medicare? If Wegovy is prescribed for its heart-protection use, that goes through your regular Part D plan — not the new $50 Medicare GLP-1 Bridge, which is for weight management only.

This is a spot where Ro's insurance concierge earns its keep, because getting heart-related coverage approved often comes down to paperwork. Ro carries FDA-approved options and helps verify coverage and run prior authorizations.

Affiliate link.

Which GLP-1 should I start with if I have sleep apnea?

If you have obesity and diagnosed moderate-to-severe obstructive sleep apnea, Zepbound is the GLP-1 to ask about first — the FDA approved it for that use in adults with obesity. The key word is diagnosed: confirm you have a sleep study on record and an actual diagnosis.

• Ask whether the diagnosis changes your coverage (sometimes it does).
• Keep your existing sleep-apnea care plan unless your clinician changes it.
• On Medicare? If Zepbound is prescribed for sleep apnea, that goes through regular Part D — not the $50 Medicare GLP-1 Bridge, which covers weight-management use only.

See our full best GLP-1 for sleep apnea guide and our full Zepbound worth-it analysis.

How much does it cost to start a GLP-1 in 2026?

The cheapest legitimate way to start depends entirely on your coverage. With commercial insurance plus a manufacturer savings card, eligible patients may pay around $25/month. Starting July 1, 2026, eligible Medicare members can pay $50/month. Cash-pay runs about $149/month for the pills and $199–$449/month for the shots. Brand-name prices have fallen so far that the old “compounded is the only way I can afford this” assumption no longer holds for many beginners.

Sources: LillyDirect, NovoCare, and Ro pricing pages; CMS (Medicare GLP-1 Bridge). All checked June 2026. Several offers expire June 30 and Aug. 31, 2026 — confirm the current number on the provider's page.

For a full breakdown by drug and payer, see GLP-1 cost without insurance.

Sesame lists a broad branded menu — Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo, and Saxenda — and accepts insurance. (Affiliate link.)

Which GLP-1 should I start with if I'm on Medicare?

A new program called the Medicare GLP-1 Bridge can cover Foundayo, Wegovy (shot or pill), or the Zepbound KwikPen for a $50 monthly copay — but only for eligible Part D members, only for weight management, and only from July 1, 2026 through December 31, 2027. If your GLP-1 is prescribed for diabetes, sleep apnea, or MASH, that goes through your regular Part D plan instead.

Which GLP-1 should I start with if I have PCOS or insulin resistance?

GLP-1 medications aren't FDA-approved specifically for PCOS, but because PCOS often comes with insulin resistance and weight gain, many people with PCOS use them for weight management under a clinician's care. The right starting medication depends on the same things as anyone else — your goal, your insurance, pill vs shot, your budget — plus your pregnancy plans, since these drugs aren't used during pregnancy or while trying to conceive.

The first conversation should cover your weight goal, your A1C or diabetes risk, whether you're planning a pregnancy soon, how you've tolerated other medications, and whether your insurance treats your diagnosis as weight management, diabetes prevention, or something else. For more, see our GLP-1 guide for women.

Which GLP-1 should I start with if I already tried one or plateaued?

If you've already taken a GLP-1, your “which should I start with” question is really a “should I switch” question. A clinician will look at your dose, how consistently you took it, your side effects, your insurance, and whether moving from semaglutide to tirzepatide (or between a pill and a shot) makes sense.

People who plateaued on semaglutide (Wegovy) sometimes see renewed progress on tirzepatide (Zepbound), since it works on a second hormone receptor. But “sometimes” is doing real work in that sentence — your dose, how long you've been on it, and your tolerance all matter, and a higher dose of what you're already taking is sometimes the better move.

Should I start with an FDA-approved or compounded GLP-1?

If an FDA-approved option is medically appropriate and you can afford it, that's usually the cleaner, lower-risk way to start. Compounded GLP-1 medications are not FDA-approved finished drugs, they are not the same product as the brand-name versions, and in mid-2026 they sit on shaky legal ground. The FDA has flagged real safety concerns and is actively moving to restrict large-scale compounding.

The price gap that once made compounded the obvious budget choice has shrunk — brand-name prices are now $149–$449 cash, $50 on Medicare, and ~$25 with insurance for eligible patients — while the legal and safety risk has gone up.

Who should NOT start a GLP-1 without closer medical review?

Some people shouldn't start a GLP-1 casually or through a quick online form. These medicines carry a boxed warning (the FDA's most serious warning) about a risk of thyroid tumors based on animal studies. Bring this list to a clinician before you pick anything off a chart:

What happens in your first month on a GLP-1?

You almost always start at the lowest dose and increase slowly over weeks — because side effects like nausea, constipation, and feeling overly full are most common early on or when the dose goes up. Your first month is mostly about tolerating the medicine and building habits, not judging your final results.

• A low starting dose that steps up over time. The starting dose is not the dose that drives most of the weight loss.
• Appetite changes — food noise quieting down, getting full faster.
• Stomach side effects that usually ease as your body adjusts. Smaller meals, plenty of water, and going slow all help.
• Protein and strength training to protect your muscle while you lose fat.

Once you know your lane, which provider should you use?

For FDA-approved, brand-name treatment with insurance help, start with Ro or Sesame. If you already have a prescription and just want the medicine, the manufacturers' own pharmacies (LillyDirect, NovoCare) can be cheapest. If you're still deciding, use our matching tool first.

Affiliate link for Ro. Compare the all-in numbers in our Ro vs LillyDirect breakdown, or see the full ranking in best GLP-1 telehealth providers.

How we picked these starting paths

We scored every starting option on the five pillars of the RX Index Score — clinical legitimacy, care quality, transparency, access, and cost — using only verified facts. Medical and regulatory claims come from primary sources (the FDA, CMS, peer-reviewed trials). Pricing comes from manufacturer and provider pages, with dates.

Frequently asked questions

Sources

• Tirzepatide vs semaglutide head-to-head (SURMOUNT-5), New England Journal of Medicine, 2025 — tirzepatide 20.2% vs semaglutide 13.7% at 72 weeks.
• Foundayo (orforglipron) FDA approval, April 1, 2026; ATTAIN-1 results (about 12.4% at highest dose) — FDA.gov; Eli Lilly press release.
• Wegovy cardiovascular indication — FDA press release, “FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight.”
• Zepbound obstructive sleep apnea indication — FDA press release.
• Wegovy pill approval (December 2025) and oral dosing rules — FDA; Ro oral GLP-1 guide.
• 2026 cash pricing — LillyDirect (Zepbound vial/KwikPen $299/$399/$449 with 45-day refill; Foundayo from $149/mo); NovoCare (Wegovy pen $199 intro through June 30, 2026, then $349; Wegovy pill from $149, 4 mg offer through Aug. 31, 2026); Ro pricing page ($39 to start, as low as $74/mo annual).
• TrumpRx (launched February 5, 2026; routes to manufacturer pricing) — STAT; AMCP; AARP.
• Medicare GLP-1 Bridge ($50/mo, July 1, 2026 – Dec. 31, 2027; eligibility by BMI/condition tiers; covered drugs) — CMS.gov.
• Compounded GLP-1 status (shortages resolved 2024–25; March 2025 court rulings; April 30, 2026 FDA 503B bulks-list proposal; 990 semaglutide / 730+ tirzepatide adverse-event reports as of May 31, 2026; salt-form and fraudulent-product warnings) — FDA.gov.